Citigroup’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.8M Sell
25,048
-10,729
-30% -$611K ﹤0.01% 2728
2025
Q4
$1.51M Buy
35,777
+32,730
+1,074% +$1.83M ﹤0.01% 2839
2025
Q3
$173K Sell
3,047
-3,890
-56% -$129K ﹤0.01% 4053
2025
Q2
$179K Sell
6,937
-1,313
-16% -$14.7K ﹤0.01% 4123
2025
Q1
$84.2K Sell
8,250
-926
-10% -$12.1K ﹤0.01% 4689
2024
Q4
$128K Buy
9,176
+501
+6% +$8.84K ﹤0.01% 4700
2024
Q3
$169K Buy
8,675
+5,998
+224% +$114K ﹤0.01% 4457
2024
Q2
$49.8K Buy
2,677
+2,672
+53,440% +$56.3K ﹤0.01% 4579
2024
Q1
$73 Sell
5
-23,843
-100% -$250K ﹤0.01% 5506
2023
Q4
$202K Buy
23,848
+18,649
+359% +$141K ﹤0.01% 3917
2023
Q3
$46.4K Buy
5,199
+4,951
+1,996% +$47.7K ﹤0.01% 4165
2023
Q2
$2.14K Sell
248
-5,553
-96% -$59.2K ﹤0.01% 5281
2023
Q1
$61.2K Sell
5,801
-2,839
-33% -$85.9K ﹤0.01% 4206
2022
Q4
$293K Sell
8,640
-272
-3% -$13.2K ﹤0.01% 3525
2022
Q3
$428K Sell
8,912
-2,914
-25% -$173K ﹤0.01% 3355
2022
Q2
$674K Sell
11,826
-1,312
-10% -$82.8K ﹤0.01% 2996
2022
Q1
$1.06M Buy
13,138
+5,159
+65% +$764K ﹤0.01% 2905
2021
Q4
$1.62M Buy
7,979
+3,900
+96% +$846K ﹤0.01% 2796
2021
Q3
$1.1M Sell
4,079
-2,020
-33% -$486K ﹤0.01% 3012
2021
Q2
$1.57M Buy
6,099
+1,724
+39% +$477K ﹤0.01% 2863
2021
Q1
$1.31M Sell
4,375
-3,145
-42% -$979K ﹤0.01% 2780
2020
Q4
$1.92M Sell
7,520
-501
-6% -$129K ﹤0.01% 2898
2020
Q3
$2M Sell
8,021
-2,054
-20% -$646K ﹤0.01% 2649
2020
Q2
$3.5M Sell
10,075
-928
-8% -$290K ﹤0.01% 2207
2020
Q1
$2.95M Buy
11,003
+4,375
+66% +$1.35M ﹤0.01% 2121
2019
Q4
$2.15M Sell
6,628
-5,621
-46% -$1.63M ﹤0.01% 2891
2019
Q3
$3.35M Buy
12,249
+6,629
+118% +$2.43M ﹤0.01% 2316
2019
Q2
$3M Sell
5,620
-1,687
-23% -$846K ﹤0.01% 2401
2019
Q1
$3.68M Sell
7,307
-1,584
-18% -$939K ﹤0.01% 2053
2018
Q4
$4.38M Buy
8,891
+2,910
+49% +$1.76M ﹤0.01% 1925
2018
Q3
$5.47M Buy
5,981
+5,664
+1,787% +$4.83M ﹤0.01% 1775
2018
Q2
$232K Sell
317
-2,116
-87% -$2.44M ﹤0.01% 4904
2018
Q1
$3.88M Buy
2,433
+2,316
+1,979% +$2.98M ﹤0.01% 2001
2017
Q4
$105K Sell
117
-7,745
-99% -$4.58M ﹤0.01% 5597
2017
Q3
$2.83M Sell
7,862
-5,691
-42% -$1.78M ﹤0.01% 2297
2017
Q2
$3.98M Buy
13,553
+569
+4% +$164K ﹤0.01% 1905
2017
Q1
$4.57M Sell
12,984
-5,840
-31% -$1.31M ﹤0.01% 1742
2016
Q4
$3.46M Buy
18,824
+11,562
+159% +$2.35M ﹤0.01% 2271
2016
Q3
$1.87M Buy
7,262
+2,643
+57% +$681K ﹤0.01% 2576
2016
Q2
$985K Sell
4,619
-1,857
-29% -$415K ﹤0.01% 2982
2016
Q1
$1.34M Buy
6,476
+5,983
+1,214% +$1.15M ﹤0.01% 2983
2015
Q4
$125K Sell
493
-2,245
-82% -$462K ﹤0.01% 5171
2015
Q3
$450K Buy
2,738
+1,980
+261% +$350K ﹤0.01% 3838
2015
Q2
$141K Sell
758
-1,195
-61% -$206K ﹤0.01% 4733
2015
Q1
$322K Sell
1,953
-1,262
-39% -$259K ﹤0.01% 4125
2014
Q4
$747K Buy
3,215
+2,882
+865% +$616K ﹤0.01% 3441
2014
Q3
$60K Buy
333
+168
+102% +$32.1K ﹤0.01% 5170
2014
Q2
$33K Sell
165
-1,674
-91% -$296K ﹤0.01% 5460
2014
Q1
$335K Sell
1,839
-1,354
-42% -$268K ﹤0.01% 3852
2013
Q4
$544K Buy
3,193
+1,066
+50% +$172K ﹤0.01% 3722
2013
Q3
$333K Buy
2,127
+1,009
+90% +$187K ﹤0.01% 3765
2013
Q2
$193K Buy
+1,118
New +$171K ﹤0.01% 4300

Other funds holding NKTR

Citigroup's NKTR Position: Q1 2026 in Review

Citigroup reduced its Nektar Therapeutics (NKTR) stake by 30% in Q1 2026, selling an estimated $611K and leaving 25,048 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Citigroup first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.47M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Citigroup held 25,048 shares of Nektar Therapeutics worth $1.8M as of Q1 2026.
  • Citigroup sold 10,729 Nektar Therapeutics shares in Q1 2026, an estimated $611K.
  • Nektar Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2728 holding.
  • Citigroup first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Nektar Therapeutics position peaked at $5.47M in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.